Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) told investors it will be presenting at American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California on 5-10 April 2024.
It intends to present data on its open-label Phase 2 SCOPE trial, investigating its cancer vaccine, SCIB1, in combination with checkpoint inhibitors (CPIs) in advanced melanoma.
SCIB1 previously demonstrated an 85% response rate among 13 first-line advanced melanoma patients, the company highlighted.
“The AACR conference is an internationally recognized annual meeting, serving as a focal point of the cancer research community where the latest advances in the cancer space can be shared amongst world-leading experts,” Scancell said in a statement.